Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 30;10(3):37400.
doi: 10.52965/001c.37400. eCollection 2022.

Daridorexant for the Treatment of Insomnia

Christopher L Robinson  1 , Rajesh Supra  2 , Evan Downs  3 , Saurabh Kataria  4 , Katelyn Parker  3 , Alan D Kaye  5 , Omar Viswanath  6 , Ivan Urits  7
Affiliations
Review

Daridorexant for the Treatment of Insomnia

Christopher L Robinson et al. Health Psychol Res. .

Abstract

Purpose of review: Insomnia is a complex sleeping disorder that affects the lives of many individuals worldwide. Insomnia often occurs in the presence of coexisting comorbidities making it a complex disorder that requires a multifactorial approach to therapy. First-line therapy is cognitive-behavioral therapy for insomnia (CBT-I). Pharmacotherapy for insomnia falls into four classes based on mechanism of action: benzodiazepine receptor agonists (BZRAs), histamine receptor antagonists, melatonin receptor agonists, and dual orexin receptor antagonists (DORAs).

Recent findings: Daridorexant is a dual orexin type 1 and types 2 (OX1 and OX2) receptor antagonist that was recently approved by the US FDA for the treatment of adults suffering from insomnia. It was shown to be effective in reducing insomnia symptoms, increasing daytime functioning, and improving the overall quality of sleep. Daridorexant offers patients relief from insomnia while avoiding the severe side effects and dependency issues of traditional treatments like benzodiazepines and sedatives.

Summary: In this article, we review the most recent data on insomnia treatments and summarize the safety and efficacy of daridorexant in treating insomnia.

Keywords: Daridorexant; Insomnia; Treatment.

PubMed Disclaimer

Conflict of interest statement

There is no conflict of interest with the authors.

References

    1. 1. Sateia MJ. International Classification of Sleep Disorders-Third Edition. Chest. 2014;146(5):1387-1394. doi:10.1378/chest.14-0970 - PubMed
    1. 2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association; 2013. doi:10.1176/appi.books.9780890425596
    1. 3. Riemann D, Benz F, Dressle RJ, et al. Insomnia disorder: state of the science and challenges for the future. Journal of Sleep Research. 2022;31(4). doi:10.1111/jsr.13604 - PubMed
    1. 4. Herring WJ, Roth T, Krystal AD, Michelson D. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J Sleep Res. 2019;28(2). doi:10.1111/jsr.12782 - PubMed
    1. 5. Dopheide JA. Insomnia overview: epidemiology, pathophysiology, diagnosis and monitoring, and nonpharmacologic therapy. Am J Manag Care. 2020;26:S76-S84. doi:10.37765/ajmc.2020.42769 - PubMed